Goal 3: Advance Translational Research

Submitted by (@wheeze)

Drug Hypersensitivity Databases

As the current chair of the Research and Training Division, I would like to convey that the AAAAI membership would like the NHLBI to consider the following in the development of its strategic plan: Drug Hypersensitivity is a growing concern for patients who are unprotected against potentially severe and lethal reactions. It would be important to generate databases to characterized the different drug reactions, their ...more »

Voting

-7 net votes
11 up votes
18 down votes
Active

Goal 2: Reduce Human Disease

Submitted by (@wheeze)

Drug Desensitization Protocols

As the current chair of the Research and Training Division, I would like to convey that the AAAAI membership would like the NHLBI to consider the following in the development of its strategic plan: Given that increasing number of patients allergic to their best medications are treated with desensitization, which allows improved quality of life and prolongs their lives, ¬†what ¬†personalized, effective and safe protocols ...more »

Voting

-9 net votes
4 up votes
13 down votes
Active

Goal 2: Reduce Human Disease

Submitted by (@wheeze)

Genetic and Molecular Tools for Drug Allergy - Hypersensitivity

As the current chair of the Research and Training Division, I would like to convey that the AAAAI membership would like the NHLBI to consider the following in the development of its strategic plan: Given that more patients are treated with newer and better targeted medications including chemotherapy, monoclonal antibodies, small molecules and others that have increased the number of hypersensitivity reactions, which ...more »

Voting

-4 net votes
10 up votes
14 down votes
Active

Goal 3: Advance Translational Research

Submitted by (@njkenyon)

Using "omics" technologies to define responders to drug therapies

Metabolomic and proteomic technologies open tremendous avenues to define at the systemic level and, in the case of the lung, the organ level response to drug and non-drug interventions. The concept of responders and non-responders to therapies is poorly defined and hampers development of biomarkers and appropriate animal models. Omics technologies can bridge these important areas. In lung disease, breath analysis could ...more »

Voting

7 net votes
13 up votes
6 down votes
Active

Goal 2: Reduce Human Disease

Submitted by (@wjones7)

Open up NCATS

The NCATS program for drug repurposing is currently only open to drugs submitted by industry (read, big Pharma). We have had the experience of working to repurpose a generic drug not on their list, and despite great Preliminary data, we could not. This program is a great idea, but needs to be opened to any company and any drug for which solid data backing efficacy and market can be applied. Why do we only want to enhance ...more »

Voting

-5 net votes
5 up votes
10 down votes
Active